Valneva SE (VALN) Liabilities and Shareholders Equity (2020 - 2026)
Valneva SE's (VALN) quarterly Liabilities and Shareholders Equity came in at $435.5 million in Q1 2026, down 14.14% year-on-year from $507.3 million in Q1 2025, and down 6.19% quarter-over-quarter from $464.3 million in Q4 2025.
Valneva SE (VALN) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Valneva SE has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $435.5 million for Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $435.5 million, down 14.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 billion (down 7.23% YoY), and the FY2025 annual result was $464.3 million, down 13.11% from the prior year.
- Liabilities and Shareholders Equity came in at $435.5 million for Q1 2026 at Valneva SE, down from $464.3 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $872.9 million in Q1 2022 to a low of $435.5 million in Q1 2026.
- The 5-year median for Liabilities and Shareholders Equity is $546.3 million (2024), against an average of $581.6 million.
- Across the five-year window, Liabilities and Shareholders Equity sank 32.2% in 2022 and rose 7.95% in 2024, its largest moves.
- Valneva SE's Liabilities and Shareholders Equity stood at $633.9 million in 2022, then fell by 21.92% to $495.0 million in 2023, then grew by 7.95% to $534.3 million in 2024, then dropped by 13.11% to $464.3 million in 2025, then decreased by 6.19% to $435.5 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $435.5 million (Q1 2026), $464.3 million (Q4 2025), and $524.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 33.89 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 23.64 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 640.56 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 435.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 435.53 Mn |
| Dec 31, 2025 | 464.26 Mn |
| Sep 30, 2025 | 524.00 Mn |
| Jun 30, 2025 | 534.99 Mn |
| Mar 31, 2025 | 507.26 Mn |
| Dec 31, 2024 | 534.33 Mn |
| Sep 30, 2024 | 567.36 Mn |
| Jun 30, 2024 | 502.44 Mn |
| Mar 31, 2024 | 546.25 Mn |
| Dec 31, 2023 | 495.00 Mn |
| Sep 30, 2023 | 566.65 Mn |
| Jun 30, 2023 | 590.82 Mn |
| Mar 31, 2023 | 633.27 Mn |
| Dec 31, 2022 | 633.92 Mn |
| Sep 30, 2022 | 703.86 Mn |
| Jun 30, 2022 | 773.73 Mn |
| Mar 31, 2022 | 872.85 Mn |
| Dec 31, 2021 | 935.03 Mn |
| Dec 31, 2020 | 535.53 Mn |